to Content

Dr. Berlin Bayer Schering Pharma Professor für Biochemie; Freier Berater im Bereich Medizin, Berlin


1972 M.D. degree, University of Munich
1974 Doctorate in Clinical Biochemistry, University of Munich
1975 moved to Rockefeller University in New York as a post-doc
1976 was appointed Assistant Professor of Chemical Biology
1982 Group Leader of Molecular Haematology, Centre Hopitalier Universitaire Vaudoise in Lausanne, Switzerland
1987 hired by Schering AG in Berlin in order to create a new Department of Molecular and Cellular Biology. Dr. Schleuning left Schering and cofounded PAION GmbH, a biopharmaceutical company with a drug portfolio largely based on Dr. Schleuning s research.
since 2004 working as an independent consultant for biotechnology and venture capital firms. Dr. Schleuning has been a pioneer in the field of genetically engineered protein drugs. One of them (Desmoteplase) is now in the last stage of clinical development. His research strategy is based on the notion that evolution has created analogues of human proteins for specific adaptations in the animal world which are suitable as drugs for medicinal interventions. Examples include snake, spider, scorpion venoms and vampire bat saliva.


DECHEMA Gesellschaft für Chemische Technik und Biotechnologie
GBM Gesellschaft für Biochemie und Molekularbiologie e.V.
Berliner Wissenschaftliche Gesellschaft e.V.
Deutsche Gesellschaft für Endokrinologie e.V.


Krätzschmar, J.; Haendler, B.; Langer, G. et al.: The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene. 105(2):229-37, 1991
Renatus, M.; Stubbs, M.T.; Huber, R et al.: Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry. 1997 36 (44):13483-93, 1997


WHO Research Fellow (1973)
DFG Research Fellow (1985-1987)
Roche Foundation Visiting Professor (1982-1983)